71
Views
7
CrossRef citations to date
0
Altmetric
Review

Pharmaceutical pricing in the developing world: issues of access to medicines

Pages 43-50 | Published online: 09 Jan 2014

References

  • World Health Organization. The World Health Report 2000. Health Systems: Improving Performance. WHO, Geneva, Switzerland (2001).
  • World Health Organization. WHO Medicines Strategy: Framework for Action in Essential Drugs and medicines Policy 2000-2003 WHO, Geneva, Switzerland (2000).
  • World Health Organization. WHO Public- Private Roles in the Pharmaceutical Sector. Implications for Equitable Access and Rational Drug Use. WHO/DAP/97.12 WHO, Geneva, Switzerland (1998).
  • Scherer FM, Watal J. Pct-TRIPS options for Access to Patented Medicines in Developing Countries Commission on Macroeconomics and Health Working Paper Series. Paper No.
  • Govindaraj R, Reich MR and Cohen JC. World Bank Pharmaceutical Discussion Paper: Human Development Network, The World Bank, September (2000).
  • Pharmaceutical Research and Manufacturers Association of America (P6RMA). Global Partnerships: Uniting to Build a Healthier TOMOITOW P6RMA, World Health Organization. The World Health Report 2000. Health Systems: Improving- Performance. WHO, Geneva, Switzerland (2001).
  • Challu P The Consequences of Pharmaceutical Product Patenting. World Comp. 15(2), 65–126 (1991).
  • Correa C. Integrating Public Health Concerns into Patent Legislation in Developing Countries. South Centre, Geneva, Switzerland (2000).
  • •A practical and accessible guide to the TRIPS Agreement and the pharmaceutical sector.
  • World Health Organization. Globalization and Access to Drugs. Perspectives on the WTO/TRIPS Agreement. WHO/DAP/98.9. WHO, Geneva, Switzerland (1999).
  • Teixeira PR The Brazilian Experience in Universal Access to Drugs. Paper delivered to the WHO/WTO Workshop on Differential Pricing and Financing of Essential Drugs, Hosbjor, Norway, 8–11 April (2001).
  • World Trade Organization. Declaration on the TRIPS agreement and public health. Ministerial Conference. Fourth Session. Doha, Qatar, 9–14 November (2001). Essential reading related to TRIPS.
  • Attaran A, Gillespie-White L. Do Patents for Antiretroviral Drugs Constrain Access to AIDS Treatment in Africa?JAIVIA 286(15), 1886–1892 (2001).
  • DeRoeck D, Levin A. Review of Financing of Immunization Programs in Developing and 7iansitional Countries. Special Initiatives Report No. 12. Partners for Health Reform. Abt Associates, Inc., Bethesda, MD, USA (1998).
  • Barton JH. Differentiated Pricing of Patented Products. Commission on Macroeconomics and Health Working Paper Series. Paper No. WG4:2, July (2001).
  • Children's Vaccine Initiative (CVI). CVI Forum: Special Vaccine Industry Issue 11, June (1996).
  • Commission of the European Communities. Accelerated action targeted at major communicable diseases within the context of poverty raduction. Communication of the Commission to the Council and the European Parliament. Brussels, 20.9.2000. COM(2000) 585 final (2001).
  • Performance and Innovation Unit (UK). Tackling the diseases of poverty. Meeting the Okinawa/Mllennium targets for HIV/AIDS, tuberculosis and malaria. PIU, Cabinet Office, London, UK (2001).
  • Voluntary Service Overseas (VSO). Drug Deals: Medicines, Development and HIV/ AIDSVSO, London, UK (2000).
  • Mossialos E. Dukes G. Affordably priced new drugs for poor populations: proposal for a global solution. Int. fRisk Safe. Med. 1(1), 1–28 (2001).
  • Mercer Management Consulting. Optimal methods to meet global demand' A pempective. Bellagio, Italy, 5 February (1997).
  • Batson A. Win-win interactions between the public and private sectors. Nature Medicine Vaccine Supplement, 4(5), 487–491 (1998).

Websites

  • Consumer Project on Technology (CPTECH). South Africa and access to pharmaceutical drugs. (2001). Available at: www.cptech.org/ip/health/sa/. (Accessed 10 Nov 2001).
  • New York Times. AIDS Drugs for Poor Nations. March 12 (2001). Available at: www.nytimes.com/2001/03/12/opinion/ 12MON1.html. (Accessed 10 Dec 2001).
  • Perez-Casas C. (2000). HIV/AIDS Medicines Pricing Report - Setting objectives: is there a political will? Update: December 2000. Campaign for Access to Essential Medicines. Medecins Sans Frontieres. Available at: www.accessmed-msf.org/resources/tools.shtm. (Accessed 10 Dec 2001).
  • World Health Organization. More equitable pricing for essential drugs: What do we mean and what are the issues? Background paper for the WHO-WTO secretariat workshop on differential pricing and financing of essential drugs, Hosbjor, Norway, 8–11 April (2001). Available at: www.who.int/medicines/library/ edm_general/who-wto-hosbjor/who-wto-hosbjor.html. (Accessed 10 Dec 2001). Essential reading on the issue of differential pricing and pharmaceuticals.
  • Fink C. How Stronger Patent Protection in India Mght Affect the Behaviour of Tiansnational Pharmaceutical Industries. Working paper 2352 (May). Washington DC: The World Bank. Available at: http:// econ.worldbank.org/docs/1106.pdf (Accessed 13 Feb 2002).
  • World Trade Organization. TRIPS and pharmaceutical patents. Fact Sheet. (April) (2000). Available at: www.wto.org/english/ tratop_e/trips_e/trips_e.htm (Accessed 12 Jan 2002).
  • World Health Organization and World Trade Organization Secretariats. Report of the workshop on differential pricing and financing of essential drugs. Final report of the proceedings. April 8–11, Hosbjor, Norway, 2001. Available at: www.wto.org/ english/tratop_ehn_hosbjor_e.htm (Accessed 8 Dec 2001). Essential reading on the issue of differential pricing and pharmaceuticals.
  • Watal J. Workshop on differential pricing and financing of essential drugs. Background Note. Prepared by consultant to WTO Secretariat (2001). Available: www.wto.org/ english/tratop_e/trips-e/ tn_hosbjor_e.htm#news. (Accessed 12 Nov 2001). Essential reading on the issue of differential pricing and pharmaceuticals.
  • International AIDS Vaccine Initiative. AIDS Vaccines for the World: Preparing Now to Assure Access. July 9. New York: IAVI (2000). Available at: www.iavi.org/pdf/ IAVI's%20Access%20Blueprint.pdf. (Accessed 10 Dec 2001).
  • UNFPA. Exploring ways to facilitate co-operation between governments and the corm nercial sector to expand access to reproductive health commodities. The UNFPA Private-Sector initiative. UNFPA Technical and Policy Division. Technical Branch (1998). Available at:www.unfpa.org/tpd/globalinitiative/ index.htm. (Accessed 11 Nov 2001).
  • Guilloux A, Moon S. Hdden Price Tags: Disease-Specific Drug Donations: Costs and Alternatives. Access to Essential Medicines Campaign. Medecins Sans Frontieres (2000). Available at: www.neglecteddiseases.org/11.pdf (Accessed 10 Dec 2001).
  • UNAIDS. Fact sheet: A global AIDS and health fund (2001). Available at: www.un.org/ga/aids/ungassfactsheets/html/ fsfund_en.htm. (Accessed 10 Dec 2001).
  • Global Fund. The Global Fund to Fight AIDS, Tuberrulosis and Malaria. News. Available at:www.globalfundatm.org/ news.html (Accessed 13 Feb 2002).
  • G8. G8: the final official notice. Genoa Summit Meeting, 2001. Available at: http:/ /genoa-g8.ideng/attualita/primo_piano/ primo_piano_13.thml (Accessed 9 Sept 2001).
  • Global Fund. The Global Fund to Fight AIDS, Tuberrulosis and Malaria. Overview Available at: www.globalfundatm.org/ overview.html (Accessed 13 Feb 2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.